Core Viewpoint - The company has obtained multiple medical device registration certificates, enhancing its product portfolio in respiratory testing and related technologies [1] Group 1: Medical Device Registrations - The company's wholly-owned subsidiary, American Hengjian, along with Harbin Oriental Gene and Wanzi Jian Bio, has acquired several medical device registration certificates [1] - The registrations include six cytokine detection kits, testosterone and prolactin testing kits, and international certifications for COVID-19 and influenza antigen combined testing kits [1] Group 2: Market Expansion - The acquisition of these certifications will improve the company's product layout in areas such as respiratory testing, time-resolved fluorescence immunochromatography, flow cytometry, and fluorescence immunoassay instruments [1] - This development is expected to facilitate the overall market expansion of related technology platform products [1] Group 3: Sales Performance - Actual sales performance will depend on the competitiveness of the products and the company's market sales capabilities [1] - Currently, it is not possible to predict the impact of these developments on the company's future operating performance [1]